CJC-1295 and Ipamorelin: what the research actually says

CJC-1295 and Ipamorelin are almost always discussed as a pair, sold as a "stack" aimed at raising growth hormone for muscle gain, fat loss, sleep, and recovery. They're actually two distinct molecules that work through different receptors, and neither has been through the kind of testing that would establish it works or is safe in people.

What each one is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. Ipamorelin is a small peptide (a pentapeptide) that mimics ghrelin and activates a separate receptor on the pituitary, also triggering growth hormone release, with a reputation in the research literature for being more selective than older growth-hormone-releasing peptides (less effect on cortisol and prolactin).² Combining a GHRH analog with a ghrelin-mimetic is the theoretical basis for stacking them: two different pathways converging on the same pituitary output.

What the evidence shows — and where it stops

Recent sports-medicine and endocrinology literature has taken a direct look at exactly this category of self-administered growth-hormone peptides. A 2026 review in Frontiers in Endocrinology examined "performance-enhancing peptides modulating the GH-IGF1 axis," explicitly framing the problem as "bridging the gap between clinical evidence and patient self-administration"² — in other words, people are using these compounds well ahead of the human data that would justify it. A companion 2026 narrative review in JBJS Reviews covered injectable peptides in sports medicine specifically for their evidence, safety, and anti-doping implications.²

Neither CJC-1295 nor Ipamorelin has published, controlled human trials establishing effective dosing, long-term safety, or the claimed combined benefit of stacking them. Most of what circulates online is anecdotal or extrapolated from older, related growth-hormone-releasing compounds.

Regulatory status: not approved, and flagged in sport

CJC-1295 and Ipamorelin are not FDA-approved drugs. Like other unapproved wellness peptides, they're sold outside the regulated pharmaceutical supply chain, typically labeled "research use only."¹ Separately, a 2026 review of peptide and peptide-analog use in sport and bodybuilding specifically discusses growth-hormone secretagogues, the class CJC-1295 and Ipamorelin belong to, as substances of concern for doping.³

"Insulin and GLP-1s are designed for specific disease, so we know who's a good candidate for them. With these newer peptides, we don't have the same level of evidence yet."

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, in the American Medical Association (April 2026)

What's actually known about safety

Because there's no established human safety record for either compound or the combination, dosing is guesswork and long-term effects, including on insulin sensitivity, fluid retention, and joint symptoms sometimes associated with elevated GH, are unstudied for this specific product category. Dr. Tam's broader point applies directly here: "unfortunately, there just isn't enough valuable, statistically significant evidence that points us to be able to recommend them safely."¹ As with any unregulated injectable, contamination and inaccurate labeling are additional, separate risks layered on top of the unknowns about the peptides themselves.

If you're considering it anyway

If your interest is genuinely about growth hormone, fat loss, or recovery, a licensed physician can evaluate whether an FDA-approved option, such as tesamorelin for a diagnosed indication, is appropriate, and can order the bloodwork to know if there's a real deficiency worth treating. Our safest way to try peptides guide covers how to find that kind of provider.